Articles related to NEUROMODULATION

Recordings from four Parkinson’s disease patients linked cuneiform and pedunculopontine nuclei activity to distinct phases of gait initiation. Freezing episodes were preceded by disrupted mesencephalic timing, though clinical translation remains early.

The NAUTILUS trial met its primary safety endpoint for responsive centromedian thalamic stimulation in drug-resistant idiopathic generalized epilepsy. The prespecified primary effectiveness endpoint was not significant, while post hoc and 18-month outcomes showed sustained seizure reductions.

Adjunctive active VNS was associated with greater suicidal ideation improvement than sham stimulation in patients with markedly treatment-resistant depression. The exploratory analysis was not powered as a confirmatory suicide-outcomes trial.

An EEG-guided neuromodulation system received FDA clearance for PTSD treatment based on a randomized controlled trial. The platform uses individualized brain activity data to guide therapy, though detailed efficacy results have not been disclosed.

The objective of the study was to characterize the real-world safety profile of TMS devices based on MAUDE-reported AEs, including symptom patterns, manufacturer-level variations, device issues, and reporting delays.

By desynchronizing pathological rhythms, neuromodulation acts to induce plastic changes in thalamocortical circuits.